Figure 4
Erlotinib reverts the effects of NSCLC-exosomes in osteoclast differentiation. (a) Confocal microscopy analysis of RAW 264.7 cells treated, for 6 days with: CRL-2868 exosomes, Erlotinib and CRL-2868 exosomes plus Erlotinib (CRL-2868 exosomes + Erlotinib) compared with RAW 264.7 control (Ctrl). Scale bar 10 µm. (b) Evaluation by quantitative Real Time PCR of mRNA expression of TRAP and MMP9 in RAW 264.7 cells treated, for 6 days, with: 20–50 μg/ml of CRL-2868 exosomes, Erlotinib and CRL-2868 exosomes plus Erlotinib. (c) MMP9 protein levels assessed by ELISA, in RAW 264.7 cells treated, for 6 days, with: 20–50 μg/ml of CRL-2868 exosomes, Erlotinib and CRL-2868 exosomes plus Erlotinib. Values are the mean ± SD of three independent experiments *p ≤ 0.05, **p ≤ 0.01. (d) TRAP staining of RAW 264.7 cells incubated with: CRL-2868 exosomes, Erlotinib, and CRL-2868 exosomes plus Erlotinib, for six days, compared with untreated RAW 264.7 cells. Scale bar 10 µm.
